Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists

Neuropharmacology

Volumn 35, Issue 12, 1996, Pages 1709-1719

  Grant, Kathleen A ^a,c   Colombo, Giancarlo ^a   Grant, Julia ^a   Rogawski, Michael A ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Human Motor Control Section   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

dizocilpine (MK 801); drug discrimination; glutamate receptor; ketamine; N methyl D aspartate antagonist; N methyl D aspartate receptor; phencyclidine; rat

Indexed keywords

1 METHYL 1,2 DIPHENYLETHYLAMINE; 5 AMINOCARBONYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5,10 IMINE; DEXOXADROL; DEXTROMETHORPHAN; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; KETAMINE; LEVOXADROL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PHENYLCYCLOPENTYLAMINE; REMACEMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG DISCRIMINATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETAMIDES; ANALYSIS OF VARIANCE; ANESTHETICS, DISSOCIATIVE; ANIMALS; CONDITIONING, OPERANT; DEXTROMETHORPHAN; DIOXOLANES; DISCRIMINATION LEARNING; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; MEMANTINE; PHENCYCLIDINE; PIPERIDINES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030483729     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00147-5     Document Type: Article

References (74)

1. Balster R.L. and Willetts J. (1988) Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists. In: Psychopharmacology: Transduction Mechanisms of Drug Stimuli, Series 4 (Colpaert F.C. and Balster R.L., Eds), pp. 122-135. Springer, Berlin.
2. Beardsley P.M., Hayes B.A., Balster R.L. The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J. Pharmacol. Exp. Ther. 252:1990;953-959.
3. Bennett D.A., Bernard P.S., Amrick C.L., Wilson D.E., Liebman J.M., Hutchison A.J. Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 250:1988;454-460.
4. Blake P.A., Yamaguchi S., Thurkauf A., Rogawski M.A. Anticonvulsant 1-phenylcycloalkylamines: two analogues with low motor toxicity when orally administered. Epilepsia. 33:1992;188-194.
5. Chen H.-S.V., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4436.
6. Collingridge G.L., Lester R.A.J. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40:1989;143-210.
7. Cone E.J., McQuinn R.L., Shannon H.E. Structure-activity relationship studies of phencyclidine derivatives in rats. J. Pharmacol. Exp. Ther. 228:1984;147-153.
8. Contreras P.C., Contreras M.L., O'Donohue T.L., Lair C.C. Biochemical and behavioral effects of sigma and PCP ligands. Synapse. 2:1988;240-243.
9. Contreras P.C., Rice K.C., Jacobson A.E., O'Donohue T.L. Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions. Eur. J. Pharmacol. 121:1986;9-18.
10. Coughenour L.L., Brahce L.J., Courtland G.G., Johnson G., Malone T., Probert A.W. and Marcoux F.W. (1988) PCP receptor binding affinity predicts potency in inhibiting glutamate induced calcium accumulation in neuronal cell cultures. In: Frontiers in Excitatory Amino Acid Research (Cavalheiro E.A., Lehmann J. and Turski L., Eds), pp. 563-566. Alan R. Liss, New York, NY.
11. Danysz W., Ebmann U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48:1994;111-118.
12. Domino E.F. and Luby E.D. (1981) Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: PCP (Phencyclidine): Historical and Current Perspectives (Domino E.F., Ed.), pp. 401-418. NPP Books, Ann Arbor, MI.
13. Ferkany J.W., Kyle D.J., Willetts J., Rzeszotarski W.J., Guzewska M.E., Ellenberger S.R., Jones S.M., Sacaan A.I., Snell L.D., Borosky S., Jones B.E., Johnson K.M., Balster R.L., Burchett K., Kawasaki K., Hoch D.B., Dingledine R. Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther. 250:1988;100-109.
14. ffrench-Mullen J.M.H., Rogawski M.A. Interaction of phencyclidine with voltage-dependent potassium channels in cultured rat hippocampal neurons: comparison with block of the NMDA receptor-ionophore complex. J. Neurosci. 9:1989;4051-4061.
15. Fleischhacker W.W., Buchgeher A., Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog. Neuropsychopharmacol. Biol. Psychiat. 10:1986;87-93.
16. France C.P., Moerschbaecher J.M., Woods J.H. MK-801 and related compounds in monkeys: discriminative stimulus effects and effects on a conditional discrimination. J. Pharmacol. Exp. Ther. 257:1991;727-734.
17. Garske G.E., Palmer G.C., Napier J.J., Griffith R.C., Freedman L.R., Harris E.W., Ray R., McCreedy S.A., Blosser J.C., Woodhead J.H., White H.S., Swinyard E.A. Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res. 9, 161-174.
18. 3H]SKF-10,047 binding sites in rat cerebral cortex. FEBS Lett. 190:1985;333-336.
19. Grant K.A., Snell L.D., Rogawski M.A., Thurkauf A., Tabakoff B. Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (±)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,1-0-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizures. J. Pharmacol. Exp. Ther. 260:1992;1017-1022.
20. Greene J.G., Porter R.H., Greenamyre J.T. ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp. Neurol. 137:1996;66-72.
21. Hein D.W., Young A.M., Herling S., Woods J.H. Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey. J. Pharmacol. Exp. Ther. 218:1981;7-15.
22. Holtzman S.G. Phencyclidine-like discriminative stimulus properties of opioids in the rat. J. Pharmacol. Exp. Ther. 214:1980;614-619.
23. Holtzman S.G. Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology. 77:1982;295-300.
24. Holtzman S.G. Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology. 116:1994;249-254.
25. Hudzik T.J., Palmer G.C. Effects of anticonvulsants in a novel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Epilepsy Res. 21:1995;183-193.
26. Irifune M., Shimizu T., Nomoto M., Fukuda T. Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex. Brain Res. 596:1992;1-9.
27. Jackson A., Sanger D.J. Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-D-aspartate receptors? Psychopharmacology. 96:1988;87-92.
28. Jones S.M., Rogawski M.A. The anticonvulsant (±)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI) selectively blocks NMDA-activated current in cultured rat hippocampal neurons: kinetic analysis and comparison with dizocilpine. Molec. Neuropharmacol. 2:1992;303-310.
29. Kelland M.D., Soltis R.P., Boldry R.C., Walters J.R. Behavioral and electrophysiological comparison of ketamine with dizocilpine in the rat. Physiol. Behav. 54:1993;547-554.
30. Koek W., Woods J.H., Colpaert F.C. N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis. J. Pharmacol. Exp. Ther. 253:1990;1017-1025.
31. Koek W., Woods J.H., Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
32. 3H-PCP binding potency measured autoradiographically. Pharmacol. Biochem. Behav. 25:1986;1051-1058.
33. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat. 51:1994;199-214.
34. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J. Pharmacol. Exp. Ther. 238:1986;739-748.
35. Legendre P., Westbrook G.L. Ifenprodil blocks N-methyl-D-aspartate receptors by a two-component mechanism. Molec. Pharmacol. 40:1991;289-298.
36. MacDonald J.F., Bartlett M.C., Mody I., Pahapill P., Reynolds J.N., Salter M.W., Schneiderman J.H., Pennefather P.S. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurons. J. Physiol. (Lond.). 432:1991;483-508.
37. Meldrum B.S. (Ed.) (1991) Excitatory Amino Acid Antagonists. Blackwell Scientific, Oxford.
38. Mendelsohn L.G., Kerchner G.A., Kalra V., Zimmerman D.M., Leander J.D. Phencyclidine receptors in rat brain cortex. Biochem. Pharmacol. 33:1984;3529-3535.
39. Netzer R., Pflimlin P., Trube G. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur. J. Pharmacol. 238:1993;209-216.
40. Palmer G.C., Murray R.J., Wilson T.C., Eisman M.S., Ray R.K., Griffith R.C., Napier J.J., Fedorchuk M., Stagnitto M.L., Garske G.E. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res. 12:1992;9-20.
41. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment in vivo. Neuropharmacology. 34:1995;1239-1258.
42. Patsalos P.N., Sander J.W. Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Safety. 11:1994;37-67.
43. Porter R.H.P., Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64:1995;614-623.
44. Pradhan S.N. Phencyclidine (PCP): some human studies. Neurosci. Biobehav. Rev. 8:1984;493-501.
45. Rabey J.M., Nissipeanu P., Korczyn A.D. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm. [P-D Sect.]. 4:1992;277-282.
46. Riederer P., Lange K.W., Kornhuber J., Danielczyk W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet. 338:1991;1022-1023.
47. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
48. Rogawski M.A., Le D.Q., Uyakul D., Pannell L.K., Subramaniam S., Yamaguchi S., Kokate T.G. Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia. 36:1995;566-571.
49. Rogawski M.A., Thurkauf A., Yamaguchi S., Rice K.C., Jacobson A.E., Mattson M.V. Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetetrahydroisoquinoline. J. Pharmacol. Exp. Ther. 249:1989;708-712.
50. Rogawski M.A., Yamaguchi S., Blake P.A., Jones S.M., Bieda M.C., Costa B.R. de and Thurkauf A. (1992) Anticonvulsant 1-phenylcycloalkylamine analogs: uncompetitive NMDA antagonists with low motor toxicity. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? (Kamenka J.-M. and Domino E.F., Eds), pp. 747-758. NPP Books, Ann Arbor, MI.
51. Rogawski M.A., Yamaguchi S., Jones S.M., Rice K.C., Thurkauf A., Monn J.A. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D-aspartate antagonist (±)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10- imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J. Pharmacol. Exp. Ther. 259:1991;30-37.
52. Sanger D.J. NMDA antagonists disrupt timing behaviour in rats. Behav. Pharmacol. 3:1992;593-600.
53. Sanger D.J., Terry P., Katz J.L. Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav. Pharmacol. 3:1992;265-268.
54. Sanger D.J., Zivkovic B. The discriminative stimulus effects of MK-801: generalization to other N-methyl-D-aspartate receptor antagonists. J. Psychopharmacol. 3:1989;198-204.
55. Shannon H.E. Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties. J. Pharmacol. Exp. Ther. 216:1981;543-551.
56. Shannon H.E. Pharmacological evaluation of N-allynormetazocine (SKF 10,047) on the basis of its discriminative stimulus properties in the rat. J. Pharmacol. Exp. Ther. 225:1983;144-152.
57. Shannon H.E. (1983b) Discriminative stimulus effects of phencyclidine: structure-activity relationships. In: Phencyclidine and Related Arylcyclohexlamines (Kamenka J.-M., Domino E.F. and Geneste P., Eds), pp. 311-336. NPP Books, Ann Arbor, MI.
58. Shannon H.E., Holtzman S.G. Evaluation of the discriminative effects of morphine in the rat. J. Pharmacol. Exp. Ther. 198:1976;54-65.
59. Siegel R.K. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. Natl. Inst. Drug Abuse Res. Monogr. Ser. 21:1978;119-147.
60. Slifer B.S., Balster R.E. Phencyclidine-like discriminative stimulus properties of the stereoisomers of dioxadrol. Subst. Alcohol Actions Misuse. 5:1984;271-280.
61. Steinberg G.K., Bell T. Clinical dose-escalation safety study of the NMDA antagonist, dextromethorphan in neurosurgical patients (abstr). Stroke. 22:1991;141.
62. Subramaniam S., Donevan S.D., Rogawski M.A. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J. Pharmacol. Exp. Ther. 276:1996;161-168.
63. Teal J.J., Holtzman S.G. Steroselectivity of the stimulus effects of morphine and cyclazocine in the squirrel monkey. J. Pharmacol. Exp. Ther. 215:1980;369-376.
64. Thurkauf A., de Costa B., Yamaguchi S., Mattson M.V., Jacobson A.E., Rice K.C., Rogawski M.A. Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogues. J. Med. Chem. 33:1990;1452-1458.
65. Tortella F.C., Musacchio J.M. Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties. Brain Res. 383:1986;314-318.
66. Tortella F.C., Robles L., Witkin J.M., Newman A.H. Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile. J. Pharmacol. Exp. Ther. 268:1994;727-733.
67. Tricklebank M.D., Singh L., Oles R.J., Preston C., Iversen S.D. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167:1989;127-135.
68. Tricklebank M.D., Singh L., Oles R.J., Wong E.H.F., Iversen S.D. A role for receptors of N-methyl-D-aspartic acid in the discriminative stimulus properties of phencyclidine. Eur. J. Pharmacol. 141:1987;497-501.
69. Walker F.O., Hunt V.P. An open label trial of dextromethorphan in Huntington's disease. Clin. Neuropharmacol. 12:1989;322-330.
70. Willetts J., Balster R.L. Phencyclidine-like discriminative stimulus properties of MK-801 in rats. Eur. J. Pharmacol. 146:1988;167-169.
71. Willetts J., Balster R.L. The discriminative stimulus effects of N-methyl-D-aspartate antagonists in phencyclidine-trained rats. Neuropharmacology. 27:1988;1249-1256.
72. Willetts J., Balster R.L., Leander J.D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11:1990;423-428.
73. Wilson T.C.M., Elsman M.S., Machulskis G.E. Quantitation of the novel anticonvulsant remacemide in rat and dog plasma and urine: application of the plasma methodology to measure the plasma protein binding of remacemide. J. Chromatogr. 582:1992;195-202.
74. Wong E.H.F., Kemp J.A., Preistley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. natn. Acad. Sci. 83:1986;7104-7108.